|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Drug Monitoring, Novel Psychoactive Substances (NPS), Qualitative, Urine
Test Code13086
CPT Codes
80346, 80352, 80354, 80364, 80371, 80375 (HCPCS: G0480)
Includes
Designer Benzodiazepines
Designer Fentanyl Analogs
Designer Opioids
Designer Stimulants
Synthetic Cannabinoids
Other Illicit Additives
NPS Comments will be automatically added to the Drug Monitoring NPS test code.
Designer Fentanyl Analogs
Designer Opioids
Designer Stimulants
Synthetic Cannabinoids
Other Illicit Additives
NPS Comments will be automatically added to the Drug Monitoring NPS test code.
Preferred Specimen
3 mL urine collected in a plastic urine container
Minimum Volume
2 mL
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Preserved samples
Methodology
Mass Spectrometry (MS)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon-Sat; Report available: 1-3 days
Reference Range
| Designer Benzodiazepines | <10 ng/mL |
| Designer Fentanyl Analogs | <5 ng/mL |
| Designer Opioids | <10 ng/mL |
| Designer Stimulants | <10 ng/mL |
| Synthetic Cannabinoids | <10 ng/mL |
| Other Illicit Additives | <10 ng/mL |
Clinical Significance
Novel psychoactive substances (NPS) are compounds designed to mimic the effects of prescription drugs, evade detection by typical drug testing methodologies, and avoid regulation. NPS can also be referred to as legal highs, Spice, Benzo Dope, Tranq Dope, or in products labelled "not for human use". NPS markets rapidly change in response to regulation from national and international agencies. These drugs are not typically detected by presumptive, immunoassay point-of-care or desktop analyzer drug tests. NPS may potentiate drug interactions with prescription medications, leading to unintended overdoses. Individuals may be exposed to illicit fentanyl or analogs, designer opioids, stimulants, and benzodiazepines, or xylazine, knowingly, or unknowingly through counterfeit prescription drugs intended to mimic common drugs such as oxycodone, hydrocodone, and alprazolam, among others. Updates and enhancements to our tested drug list are made from time to time based on surveillance data from the Center for Forensic Science Research and Education (CFSRE) and clinical patient trends. A complete and up to date list of the analytes contained in each drug class can be found at the bottom of each report and in our online FAQ.
